Baltimore-based Pharos secures Zika vaccine tech


The race to advance a Zika vaccine will have a new entrant in Baltimore-based Pharos Biologicals. The development-stage company this week announced it has been awarded technology for influenza and flavivirus vaccines from the Johns Hopkins University School of Medicine.

The patented Lysosome-Associated Membrane Protein DNA vaccine technology, the company says, features a rapid development timeline, is highly stable and directly delivers antigens to cell proteins to prompt immune responses. Invented by Johns Hopkins professor and Pharos founder Dr. J. Thomas August, the vaccines utilize normal cellular mechanisms to bolster vaccine immune responses and do not contain live virus, the company’s statement said.

Pharos anticipates it will be able to start Phase I testing with the platform in Zika this fall. Back in February, Plymouth Meeting, PA-based Inovio said it’s shooting to start a Phase I Zika vaccine trial on the same timeline while the U.S. National Institutes of Health that month said it’s looking to start Phase I testing this summer.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Pharos joins a Zika vaccine R&D scramble that features more than 18 companies and organizations as the virus has raced around the globe to more 50 countries and territories, according to WHO figures. Founded in 2015, the Baltimore-based company also has aspirations in dengue and influenza. David Wise, an executive in the med-tech startup and venture capital community in Baltimore, serves as CEO.

In October 2015, the LAMP vaccine tech showed commercial promise when Immunomic Therapeutics sold a license for allergen vaccines to Japan’s Astellas for $300 million; Johns Hopkins previously awarded that license.

- here’s the release

Related Article:
Health agencies inform on Zika vaccine timeline

An image predicting the spread of Zika, courtesy of


Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.